ArticleBMC cardiovascular disorders2025
A case report on the implantation of a leadless pacemaker in a patient with eosinophilic fasciitis and third-degree atrioventricular block.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Eosinophilic fasciitis (EF) is a rare connective tissue disorder characterized by the involvement of the dermis, subcutaneous tissue, and fascia. The treatment for EF usually involves long-term use of glucocorticoids and immunosuppressants. Patients with EF are at risk of developing third-degree atrioventricular (AV) block during the course of the disease. The distinctive features of EF, the side effects of its treatment, and the inherent limitations of transvenous pacemakers (TVPs) present significant challenges in the management of patients with EF who also have third-degree AV block. We present the case of a 64-year-old Chinese male diagnosed with EF and concomitant third-degree AV block. Given the patient's skin tissue characteristics, the increased risk of infection associated with long-term immunosuppressive therapy, and the potential complications related to TVPs we chose to implant a leadless pacemaker(LP) in the apical region of the right ventricle. This case report underscores the importance of identifying potential cardiovascular complications in EF patients treated with corticosteroids and immunosuppressants. It also highlights the clinical benefit of LP implantation in managing patients with EF and third-degree AV block, especially in terms of minimizing device-related complications and infection risks. This study offers a fresh perspective on the treatment of EF patients who have third-degree AV block and advocates for the use of LPs as a preferred option for cardiac pacing in this patient group. Further research is warranted to evaluate the indications and potential benefits of LPs in a wider range of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.